These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8117605)

  • 1. CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy.
    Fairey AF; Mead GM; Jones HW; Sweetenham JW; Whitehouse JM
    Ann Oncol; 1993 Dec; 4(10):857-60. PubMed ID: 8117605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.
    Radford JA; Rohatiner AZ; Ryder WD; Deakin DP; Barbui T; Lucie NP; Rossi A; Dunlop DJ; Cowan RA; Wilkinson PM; Gupta RK; James RD; Shamash J; Chang J; Crowther D; Lister TA
    J Clin Oncol; 2002 Jul; 20(13):2988-94. PubMed ID: 12089229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
    Hancock BW; Gregory WM; Cullen MH; Hudson GV; Burton A; Selby P; Maclennan KA; Jack A; Bessell EM; Smith P; Linch DC; ;
    Br J Cancer; 2001 May; 84(10):1293-300. PubMed ID: 11355937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.
    Saletti P; Zucca E; Gueneau M; Peccatori F; Cavalli F; Martinelli G
    Leuk Lymphoma; 1999 Apr; 33(3-4):313-9. PubMed ID: 10221511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.
    Radford JA; Crowther D; Rohatiner AZ; Ryder WD; Gupta RK; Oza A; Deakin DP; Arnott S; Wilkinson PM; James RD
    J Clin Oncol; 1995 Sep; 13(9):2379-85. PubMed ID: 7666097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ChlVPP chemotherapy in advanced Hodgkin's disease.
    McKendrick JJ; Mead GM; Sweetenham J; Jones DH; Williams CJ; Ryall R; Whitehouse JM
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):557-61. PubMed ID: 2703008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcome of advanced Hodgkin's disease based on using an alternating program ChLVPP (chlorambucil, vinblastine, procarbazine, prednisone) and ABV (doxorubicin, bleomycin, vinblastine)].
    Komarnicki M; Balcerzak A; Górski P; Pawlak L; Hansz J
    Acta Haematol Pol; 1994; 25(4):363-8. PubMed ID: 7531381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
    Cullen MH; Stuart NS; Woodroffe C; Murphy A; Fletcher J; Blackledge GR; Child JA; Grieve RJ; Jones EL
    J Clin Oncol; 1994 Apr; 12(4):779-87. PubMed ID: 7512132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group.
    Ann Oncol; 1995 Feb; 6(2):167-72. PubMed ID: 7786824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
    Harris MA; Radford JA; Deakin DP; James RD; Swindell R; Cowan RA
    Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):53-7. PubMed ID: 14768756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity.
    Vose JM; Bierman PJ; Anderson JR; Weisenburger D; Moravec DF; Sorensen S; Hutchins M; Dowling MD; Howe D; Okerbloom J
    J Clin Oncol; 1991 Aug; 9(8):1421-5. PubMed ID: 2072145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease.
    Holte H; Mella O; Wist E; Telhaug R; Hannisdal E; Abrahamsen AF
    Acta Oncol; 1996; 35 Suppl 8():73-80. PubMed ID: 9073051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.
    Cervantes F; Reverter JC; Montserrat E; Rozman C
    Cancer Treat Rep; 1986 May; 70(5):665-7. PubMed ID: 3708614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ChlVPP--an effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease.
    Vose J; Armitage J; Weisenburger D; Moravec D; Hutchins M; Howe D; Sorensen S; Dowling M; Okerbloom J; Pevnick W
    Am J Clin Oncol; 1988 Aug; 11(4):423-6. PubMed ID: 3407620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.
    Druker BJ; Rosenthal DS; Canellos GP
    Cancer; 1989 Mar; 63(6):1060-4. PubMed ID: 2917308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
    Brusamolino E; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Bernasconi P; Astori C; Lazzarino M
    Ann Oncol; 1994 May; 5(5):427-32. PubMed ID: 7521204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.